Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases. Its lead candidate is NXC-201, a CAR-T cell therapy currently in clinical trials.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.